8-K - Bone Biologics Corp (0001419554) (Filer)

424B4 - Bone Biologics Corp (0001419554) (Filer)

EFFECT - Bone Biologics Corp (0001419554) (Filer)

8-K - Bone Biologics Corp (0001419554) (Filer)

S-3 - Bone Biologics Corp (0001419554) (Filer)

S-1 - Bone Biologics Corp (0001419554) (Filer)

8-K - Bone Biologics Corp (0001419554) (Filer)

8-K - Bone Biologics Corp (0001419554) (Filer)

10-Q - Bone Biologics Corp (0001419554) (Filer)

DEF 14A - Bone Biologics Corp (0001419554) (Filer)

Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW)), a developer of orthobiologic products for spine fusion markets, today announced the closing of its previously announced public offering of an aggregate of 1,250,000 shares of its common stock (or common stock equivalents in lieu thereof), Series D warrants to purchase up to 1,250,000 shares of common stock and Series E short-term warrants to purchase up to 1,250,000 shares of common stock, at a public offering price of $4.00 per share (or common stock equivalent in lieu thereof) and accompanying warrants. The Series D warrants have an exercise price of $4.00 per share, are exercisable immediately upon issu

Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW)), a developer of orthobiologic products for spine fusion markets, today announced the pricing of its public offering of an aggregate of 1,250,000 shares of its common stock (or common stock equivalents in lieu thereof), Series D warrants to purchase up to 1,250,000 shares of common stock and Series E short-term warrants to purchase up to 1,250,000 shares of common stock, at a public offering price of $4.00 per share (or common stock equivalent in lieu thereof) and accompanying warrants. The Series D warrants will have an exercise price of $4.00 per share, will be exercisable immediately upon issuance and wil

Bone Biologics Corporation ("Bone Biologics" or the "Company) (NASDAQ:BBLG, BBLGW)), a developer of orthobiologic products for spine fusion markets, announces the filing of a patent application with the United States Patent and Trademark Office (USPTO) for its novel NELL-1 protein. The patent application is directed to compositions of rhNELL-1 polypeptide and uses thereof for treating bone conditions. "This patent application marks a major milestone in our mission to bring effective treatments to spine fusion patients," said Jeffrey Frelick, Chief Executive Officer of Bone Biologics. The patent application, if approved, will strengthen Bone Biologics' intellectual property portfolio a

Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW)), a developer of orthobiologic products for spine fusion markets, today announced that it has received notice from The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Rule") for continued listing on the Nasdaq Capital Market. Bone Biologics is now in compliance with all applicable listing standards and its common stock will continue to be listed on the Nasdaq Capital Market. Bone Biologics was notified by Nasdaq on April 7, 2025 that it was not in compliance with the Rule because its c

Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW)), a developer of orthobiologic products for spine fusion markets, today announced a planned reverse stock split of its shares of common stock at a ratio of 1-for-6. The reverse stock split will take effect as of 12:01 a.m. ET, on Tuesday, June 10, 2025, and shares of Bone Biologics are expected to trade on a post-split basis on Nasdaq under the existing trading symbol, "BBLG," at the market open on June 10, 2025. At the Company's annual meeting of stockholders held on May 30, 2025, stockholders approved an amendment to the Company's Amended and Restated Certificate of Incorporation to implement a reverse s

Brings 30+ years of commercial experience in the orthopedic and spine industry Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW))), a developer of orthobiologic products for spine fusion markets, announces the appointment of Phillip T. Meikle to the Company's board of directors, effective immediately. Mr. Meikle succeeds Don R. Hankey, who retired from the Board following seven years of service. The number of directors of Bone Biologics remains at four. Mr. Meikle most recently was president and chief executive officer of Biosystems of New England, Inc., an orthopedic distribution company that he founded in 1992 and sold to Stryker Corporation in 2019. He

Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW))), a developer of orthobiologic products for spine fusion markets, announces that Jeffrey Frelick, chief executive officer, will present virtually at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 in New York City. Bone Biologics' company presentation will be available here beginning on Monday, September 9th at 7:00 a.m. Eastern time. The presentation will be available on the company's website for a period of time here. Management is available throughout the conference for virtual one-on-one meetings. Institutional investors and industry professionals can regis

Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW))), a developer of orthobiologic products for spine fusion markets, today announced that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of 781,251 shares of its common stock having an exercise price of $2.43 per share, originally issued in March 2024. The issuance of the shares of common stock issuable upon exercise of the existing warrants is registered pursuant to an effective registration statement on Form S-1 (File No. 333-276771). H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. In consideration for t

Reminder: Management "CEO Chat" with Zacks Small-Cap Research Analyst Begins Today at 11 a.m. Eastern Time Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW))), a developer of orthobiologic products for spine fusion markets, announces that the first two patients have been treated in the multicenter, prospective, randomized pilot clinical study of the Company's NB1 bone graft device. NB1 is NELL-1 protein combined with demineralized bone matrix (DBM) to provide rapid, specific and guided control over bone regeneration. This pilot clinical study will evaluate NB1 in 30 adult subjects who undergo transforaminal lumbar interbody fusion (TLIF) to treat degene

BURLINGTON, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW))), a developer of orthobiologic products for spine fusion markets, announces that Jeffrey Frelick, the Company's president and chief executive officer, and Deina Walsh, chief financial officer, will be interviewed by Zacks Small-Cap Research analyst Brad Sorensen, CFA in a "CEO Chat" on June 20th at the Life Science Investor Forum with Virtual Investor Conference hosted by VirtualInvestorConferences.com. The interview will begin at 11:00 a.m. Eastern time and can be viewed here. Investors are encouraged to preregister to expedite participation an